Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

Name:	us-gaap_GoodwillImpairmentLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Goodwill and Other Intangible Assets - Goodwill Impairment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Impairment
Goodwill impairment	$ 37,712,000	$ 19,453,000
Goodwill	8,637,000	46,349,000	$ 8,637,000	$ 46,349,000	$ 65,802,000
BioPharma
Impairment
Goodwill impairment	37,712,000	19,453,000	37,700,000
Goodwill		37,712,000		37,712,000	57,165,000
Consumer Health
Impairment
Goodwill impairment	0
Goodwill	8,637,000	8,637,000	8,637,000	$ 8,637,000	$ 8,637,000
Reporting unit, fair value		5,900,000
Reporting unit, carrying value	$ (2,200,000)	$ 500,000	$ (2,200,000)